JP2024502295A - 遺伝子治療において交流電場を使用するための方法及び組成物 - Google Patents
遺伝子治療において交流電場を使用するための方法及び組成物 Download PDFInfo
- Publication number
- JP2024502295A JP2024502295A JP2023539028A JP2023539028A JP2024502295A JP 2024502295 A JP2024502295 A JP 2024502295A JP 2023539028 A JP2023539028 A JP 2023539028A JP 2023539028 A JP2023539028 A JP 2023539028A JP 2024502295 A JP2024502295 A JP 2024502295A
- Authority
- JP
- Japan
- Prior art keywords
- electric field
- vector
- cell
- alternating electric
- frequency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36002—Cancer treatment, e.g. tumour
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130449P | 2020-12-24 | 2020-12-24 | |
| US63/130,449 | 2020-12-24 | ||
| PCT/IB2021/062198 WO2022137171A2 (en) | 2020-12-24 | 2021-12-22 | Methods and compositions for using alternating electric fields in gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502295A true JP2024502295A (ja) | 2024-01-18 |
| JP2024502295A5 JP2024502295A5 (cg-RX-API-DMAC7.html) | 2025-01-07 |
Family
ID=80121763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539028A Pending JP2024502295A (ja) | 2020-12-24 | 2021-12-22 | 遺伝子治療において交流電場を使用するための方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220203088A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267236B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024502295A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116615268A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022137171A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7886853B2 (ja) * | 2020-09-18 | 2026-07-08 | ノボキュア ゲーエムベーハー | コロナウイルスを処置するための方法及び組成物 |
| JP2025520663A (ja) * | 2022-06-21 | 2025-07-03 | ノボキュア ゲーエムベーハー | 交流電場とcrispr-casシステムを用いた症状および疾患の治療システムおよび方法 |
| CN115845254B (zh) * | 2022-11-23 | 2024-02-02 | 湖南安泰康成生物科技有限公司 | 小细胞肺癌治疗系统以及交变电场发生装置 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200009376A1 (en) * | 2018-07-03 | 2020-01-09 | Edwin Chang | Using Alternating Electric Fields to Increase Cell Membrane Permeability |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US6261834B1 (en) | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
| WO1999011771A1 (en) * | 1997-09-04 | 1999-03-11 | Science Research Laboratory, Inc. | Cell separation using electric fields |
| SE9704076D0 (sv) * | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
| US7016725B2 (en) | 2001-11-06 | 2006-03-21 | Standen Ltd. | Method and apparatus for destroying dividing cells |
| US8447395B2 (en) | 2000-02-17 | 2013-05-21 | Novocure Ltd | Treating bacteria with electric fields |
| US20040092860A1 (en) * | 2000-07-26 | 2004-05-13 | Dev Nagendu B. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| WO2005115535A2 (en) | 2004-04-23 | 2005-12-08 | Novocure Ltd. | Treating a tumor or the like with electric fields at different frequencies |
| CN102488967B (zh) * | 2004-12-27 | 2016-03-30 | 诺沃库勒有限公司 | 利用电场从不同方向治疗肿瘤等 |
| EP3143124B1 (en) * | 2014-05-12 | 2025-01-22 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US20200308560A1 (en) * | 2017-06-26 | 2020-10-01 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
| KR102793500B1 (ko) * | 2018-05-02 | 2025-04-14 | 그랜드 디케이드 디벨로프먼츠 리미티드 | 전기천공 시스템, 방법, 및 장치 |
| WO2020047387A1 (en) * | 2018-08-31 | 2020-03-05 | Thomas Jefferson University | In vivo genetic engineering of antigen responsive cells |
| CN113164525B (zh) * | 2018-10-23 | 2025-03-14 | 利兰·斯坦福青年大学托管委员会 | 在基于干细胞的疗法中使用交变电场预防和治疗畸胎瘤形成 |
-
2021
- 2021-12-22 JP JP2023539028A patent/JP2024502295A/ja active Pending
- 2021-12-22 EP EP21851628.4A patent/EP4267236B1/en active Active
- 2021-12-22 US US17/559,228 patent/US20220203088A1/en active Pending
- 2021-12-22 CN CN202180086830.9A patent/CN116615268A/zh active Pending
- 2021-12-22 WO PCT/IB2021/062198 patent/WO2022137171A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200009376A1 (en) * | 2018-07-03 | 2020-01-09 | Edwin Chang | Using Alternating Electric Fields to Increase Cell Membrane Permeability |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4267236A2 (en) | 2023-11-01 |
| EP4267236B1 (en) | 2026-06-24 |
| CN116615268A (zh) | 2023-08-18 |
| WO2022137171A2 (en) | 2022-06-30 |
| US20220203088A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10709797B2 (en) | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy | |
| JP2022163182A (ja) | 腫瘍溶解性ウイルスによるPTEN-Longの発現 | |
| US20220203088A1 (en) | Methods And Compositions For Using Alternating Electric Fields In Gene Therapy | |
| Kaur et al. | Addressing the challenge: current and future directions in ovarian cancer therapy | |
| Rouanet et al. | Gene therapy for pancreatic cancer: specificity, issues and hopes | |
| ES2743507T3 (es) | Inmunoterapia resistente a fármaco para el tratamiento de un cáncer | |
| McDonald et al. | Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma | |
| US12385067B2 (en) | Compositions and therapeutic methods of microRNA gene delivery | |
| CN101495156A (zh) | 用于癌症和其他疾病的亲病灶性靶向基因递送系统 | |
| WO2021121166A1 (zh) | 用于癌症治疗的多靶向siRNA | |
| US20220040329A1 (en) | Inducible expression cassette, and uses thereof | |
| EP4342985A2 (en) | Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components | |
| KR20120132594A (ko) | 마이크로rna를 이용한 조절을 통한 암 특이적 유전자 치료제 | |
| JP5486502B2 (ja) | 癌治療用の多数の発現カセットを含む構造体 | |
| JP5550803B2 (ja) | 新規アデノウイルスを用いた癌治療方法及び組成物 | |
| US20230390320A1 (en) | Cancer-specific trans-splicing ribozyme expressing immune checkpoint inhibitor, and use thereor | |
| CN118186004A (zh) | 一种响应缺氧环境控制目的基因表达的系统及其用途 | |
| Kang et al. | The piggyBac transposon is an integrating non‐viral gene transfer vector that enhances the efficiency of GDEPT | |
| Alavi et al. | Novel approaches and limitations in viral gene therapy of cancer diseases | |
| Xu et al. | Pancreatic cancer: gene therapy approaches and gene delivery systems | |
| US20170247693A1 (en) | Combinatorial treatment of chemotherapy and armed viruses targeting tumor | |
| ITMI20011138A1 (it) | Vettore e metodi di impiego per l'espressione selettiva di geni in siti di angiogenesi in vivo | |
| Ichikawa et al. | Effects of Inhalable Gene Drug Transfection as A Novel Gene Therapy for Non-Small Cell Lung Cancer and Malignant Pleural Mesothelioma | |
| CN118286157A (zh) | 一种用于原位和转移肺癌治疗的可吸入仿生脂质体及其制备方法和应用 | |
| Mishra et al. | Gene Therapy for Treatment of Pancreatic Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260402 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260623 |